Literature DB >> 24850188

Mobile phone messages to provide support to women during the home phase of medical abortion in South Africa: a randomised controlled trial.

Deborah Constant1, Katherine de Tolly2, Jane Harries3, Landon Myer4.   

Abstract

OBJECTIVES: Home use of misoprostol for medical abortion is more convenient for many women than in-clinic use but requires management of abortion symptoms at home without provider backup. This study evaluated whether automated text messages to women undergoing medical abortion can reduce anxiety and emotional discomfort, and whether the messages can better prepare women for symptoms they experience. STUDY
DESIGN: A multisite randomized controlled trial was conducted in which women undergoing early medical abortion were allocated to receive standard of care (SOC) only (n=235) or SOC+a messaging intervention (n=234). Consenting women were interviewed at the clinic after taking mifepristone and again at their follow-up clinic visit 2-3 weeks later; the intervention group received text messages over the duration of this period. Emotional outcomes were evaluated using the Hospital Anxiety and Depression Scale, Adler's 12-item emotional scale and the Impact of Event Scale-Revised. Preparedness for the abortion symptoms and overall satisfaction with the procedure were assessed using 4-point Likert-type scales.
RESULTS: Between baseline and follow-up, anxiety decreased more (p=0.013), and less emotional stress was experienced (adjusted for baseline anxiety, p=0.015), in the intervention compared to the SOC group. Participants in the intervention group were also more likely to report that they felt very well prepared for the bleeding (p<0.001), pain (p=0.042) and side effects (p=0.027) they experienced. Acceptability and other negative emotions relating to the abortion did not differ between study groups. Ninety-nine percent of the intervention group stated that they would recommend the messages to a friend having the same procedure.
CONCLUSIONS: Text messages to women following mifepristone administration for early medical abortion may assist them in managing symptoms and appear highly acceptable to recipients. IMPLICATION STATEMENT: This randomized controlled trial provides evidence for the effectiveness of text messages following mifepristone administration in strengthening medical abortion care. The messages were associated with significant reductions in women's anxiety and stress during the abortion process; they improved preparedness for the abortion symptoms experienced and appeared highly acceptable.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Acceptability; Medical abortion; Mental health; South Africa; Text messaging

Mesh:

Substances:

Year:  2014        PMID: 24850188     DOI: 10.1016/j.contraception.2014.04.009

Source DB:  PubMed          Journal:  Contraception        ISSN: 0010-7824            Impact factor:   3.375


  23 in total

1.  Use of short messaging services to assess depressive symptoms among refugees in South Africa: Implications for social services providing mental health care in resource-poor settings.

Authors:  Andrew Tomita; Ka Muzombo Kandolo; Ezra Susser; Jonathan K Burns
Journal:  J Telemed Telecare       Date:  2015-09-24       Impact factor: 6.184

Review 2.  Pain management for medical abortion before 14 weeks' gestation.

Authors:  John J Reynolds-Wright; Mulat A Woldetsadik; Chelsea Morroni; Sharon Cameron
Journal:  Cochrane Database Syst Rev       Date:  2022-05-13

Review 3.  Clients' perceptions and experiences of targeted digital communication accessible via mobile devices for reproductive, maternal, newborn, child, and adolescent health: a qualitative evidence synthesis.

Authors:  Heather Mr Ames; Claire Glenton; Simon Lewin; Tigest Tamrat; Eliud Akama; Natalie Leon
Journal:  Cochrane Database Syst Rev       Date:  2019-10-14

4.  Self-assessment of eligibility for early medical abortion using m-Health to calculate gestational age in Cape Town, South Africa: a feasibility pilot study.

Authors:  Mariette Momberg; Jane Harries; Deborah Constant
Journal:  Reprod Health       Date:  2016-04-16       Impact factor: 3.223

5.  Improving access to safe abortion in a rural primary care setting in India: experience of a service delivery intervention.

Authors:  Kirti Iyengar; Sharad D Iyengar
Journal:  Reprod Health       Date:  2016-05-10       Impact factor: 3.223

Review 6.  Meet us on the phone: mobile phone programs for adolescent sexual and reproductive health in low-to-middle income countries.

Authors:  Nicole B Ippoliti; Kelly L'Engle
Journal:  Reprod Health       Date:  2017-01-17       Impact factor: 3.223

7.  Efficacy of text-message reminders on paediatric malaria treatment adherence and their post-treatment return to health facilities in Kenya: a randomized controlled trial.

Authors:  Ambrose O Talisuna; Amos Oburu; Sophie Githinji; Josephine Malinga; Beatrice Amboko; Philip Bejon; Caroline Jones; Robert W Snow; Dejan Zurovac
Journal:  Malar J       Date:  2017-01-25       Impact factor: 2.979

8.  Women's views and experiences of a mobile phone-based intervention to support post-abortion contraception in Cambodia.

Authors:  Chris Smith; Sokhey Ly; Vannak Uk; Ruby Warnock; Caroline Free
Journal:  Reprod Health       Date:  2017-06-12       Impact factor: 3.223

9.  The EQ-5D-3L administered by text message compared to the paper version for hard-to-reach populations in a rural South African trauma setting: a measurement equivalence study.

Authors:  Henry G Burnand; Samuel E McMahon; Adrian Sayers; Tembisa Tshengu; Norrie Gibson; Ashley W Blom; Michael R Whitehouse; Vikki Wylde
Journal:  Arch Orthop Trauma Surg       Date:  2020-08-12       Impact factor: 3.067

10.  Targeted client communication via mobile devices for improving sexual and reproductive health.

Authors:  Melissa J Palmer; Nicholas Henschke; Gemma Villanueva; Nicola Maayan; Hanna Bergman; Claire Glenton; Simon Lewin; Marita S Fønhus; Tigest Tamrat; Garrett L Mehl; Caroline Free
Journal:  Cochrane Database Syst Rev       Date:  2020-07-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.